医学
血管舒张
重组组织纤溶酶原激活剂
冲程(发动机)
心脏病学
内科学
组织纤溶酶原激活剂
溶栓
麻醉
缺血性中风
缺血
心肌梗塞
机械工程
工程类
改良兰金量表
作者
Ziad El-Zammar,Julius Gene Latorre,Dongliang Wang,Shyama Satyan,E Elnour,Adham Kamel,Ashok Devasenapathy,Y Lodi
标识
DOI:10.1111/j.1749-6632.2012.06753.x
摘要
Treatment of acute ischemic stroke (AIS) is an evolving field. New treatment options are still needed in order to achieve greater success rates for arterial recanalization. Intra-arterial therapy (lAT) is an option for AIS patients who are not good candidates for intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA) or where it has failed. While good data establishing the role of IAT in AIS management are lacking, the potential clinical efficacy of IAT is based on the premise that recanalization and reperfusion may result in better clinical outcome. Although lAT recanalization and reperfusion rates of large vessel occlusion are much higher than they are for i.v. rt-PA, IAT's radiological efficacy is still far from perfect. Vasodilator use during IAT for AIS may increase the recanalization and reperfusion rates of such therapy. In this report, we describe the radiographic and clinical outcomes in a cohort of AIS patients who received intra-arterial (i.a.) vasodilators during IAT and summarize the role of i.a. vasodilators in the process of recanalization and reperfusion.
科研通智能强力驱动
Strongly Powered by AbleSci AI